Pfiz­er con­sid­ers an­tivi­ral op­tions as Paxlovid use sky­rock­ets amid wor­ries of re­sis­tance

When Pfiz­er’s Covid-19 an­tivi­ral Paxlovid first hit the shelves last De­cem­ber, it was wide­ly seen as the best op­tion to keep those at high risk of hos­pi­tal­iza­tion out of the hos­pi­tal.

But that ear­ly cau­tion with re­gard to who re­ceived the pill has gen­er­al­ly been thrown in­to the wind as al­most a mil­lion Amer­i­cans per month (or about 1 in every 4 of­fi­cial­ly re­port­ed Covid-19 case) now us­es the an­tivi­ral, ac­cord­ing to the lat­est US gov­ern­ment da­ta. The spike in us­age comes as phar­ma­cists are now al­lowed to of­fer Paxlovid in the US, and as Pfiz­er be­gins to weigh its op­tions with re­gard to com­bo treat­ments and a sec­ond-gen­er­a­tion an­tivi­ral.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER